You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大药厂(00950.HK)回升5.5%曾高见6.22元 富瑞首予「买入」评级
阿思达克 07-22 15:17
上周五表示附属治疗官颈癌药物已向国家药监局提交认定申请的李氏大药厂(00950.HK)今天获富瑞金融首予「买入」评级,该股回吐守稳10天线,今天逆市曾弹7.4%高见6.22元,现造6.11元,回升5.5%,成交增至318万股,涉资1,924万元。

大摩上周二将李氏大药厂评级由「与大市同步」升至「增持」,目标价上调60%至8元,同时将2021-2022年盈测上调4%-5%。报告指,集团在研产品线丰富将推动2021年及之後业绩增长,料未来12个月或有超过10种药物获批,且更多药物已进入关键性试验,加上已宣布考虑分拆眼科药品开发业务COPFL上市,有望释放价值。该股当日曾升至6.75元逼近五个月高遇压。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account